A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 1, 2000, Pages 7-16

  Fu, Karen K ^a   Pajak, Thomas F ^b   Trotti, Andy ^c   Jones, Christopher U ^e   Spencer, Sharon A ^d   Phillips, Theodore L ^a   Garden, Adam S ^f   Ridge, John A ^g   Cooper, Jay S ^h   Ang, K Kian ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RTOG Statistical Unit   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Radiation Oncology Center   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h NEW YORK UNIVERSITY   (United States)

Author keywords

Accelerated fractionation; Fractionation; Head and neck cancer; Hyperfractionation; Radiotherapy

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE TIME EFFECT RELATION; ESOPHAGUS INJURY; FEMALE; GASTROINTESTINAL DISEASE; HEAD AND NECK CANCER; HUMAN; INTERMETHOD COMPARISON; LARYNX INJURY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MUSCLE INJURY; OTOTOXICITY; PHARYNX DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND DISEASE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS FAT DISORDER; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIATION INJURIES; TIME FACTORS; TREATMENT FAILURE;

EID: 18544409287     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00663-5     Document Type: Article

References (44)

1. Withers H.R. Biologic basis for altered fractionation schemes. Cancer. 55:1985;2086-2095.
2. Ang K.K., Peters L.J. Principles and practices of oncology. PPO Updates. 4:1994;1-15.
3. Ang K.K. Altered fractionation trials in head and neck cancer. Semin Radiat Oncol. 8:1998;230-236.
4. Marcial V.A., Pajak T.F., Chang C., Tupchong L., Stetz J. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality Preliminary report by the Radiation Therapy Oncology Group (RTOG) . Int J Radiat Oncol Biol Phys. 13:1987;41-47.
5. Cox J.D., Pajak T.F., Marcial V.A., et al. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts Preliminary report of Radiation Therapy Oncology Group protocol 83-13 . Int J Radiat Oncol Biol Phys. 18:1990;515-521.
6. Cox J.D., Pajak T.F., Marcial V.A., et al. ASTRO Plenary Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: Results from Radiation Therapy Oncology Group protocol 8313 . Int J Radiat Oncol Biol Phys. 20:1991;1191-1195.
7. Fu K.K., Pajak T.F., Marcial V.A., et al. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer Long-term follow-up results of RTOG 83-13 [see comments] . Int J Radiat Oncol Biol Phys. 32:1995;577-588.
8. Fu K.K., Pajak T.F., Ang K.K., Byhardt R.W., Maor M.H., Beitler J.J. Randomized Phase I/II trial of two variants of accelerated fractionation radiotherapy regimens for advanced head and neck cancer Results of RTOG 88-09 . Int J Radiat Oncol Biol Phys. 32:1995;589-598.
9. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [editorial]. Int J Radiat Oncol Biol Phys. 31:1995;1341-1346.
10. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis. 27:1974;365-375.
11. Dunnett C.W. A multiple comparison procedure from comparing several treatments with a control. J Am Stat Assoc. 50:1995;1096-1121.
12. Bristol D. Designing clinical trials for two-sided multiple comparisons with a control. Control Clin Trials. 10:1989;142-152.
13. Lee D.J., Pajak T., Marcial V.A., et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherpay plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys. 32:1995;567-576.
14. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep. 5:1966;163-170.
16. Kalbfleish JD, Prentice RL. The statistical analysis of failure times data. New York: John Wiley; 1980.
17. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 16:1988;1141-1154.
18. Wang C.C., Blitzer P.H., Suit H.D. Twice-a-day radiation therapy for cancer of the head and neck. Cancer. 55:1985;2100-2104.
19. Wang C.C., Suit H.D., Blitzer P.H. Twice-a-day radiation therapy for supraglottic carcinoma. Int J Radiat Oncol Biol Phys. 12:1986;3-7.
20. Wang C.C. Local control of oropharyngeal carcinoma after two accelerated hyperfractionation radiation therapy schemes. Int J Radiat Oncol Biol Phys. 14:1988;1143-1146.
21. Wang C.C. Accelerated hyperfractionation radiation therapy for carcinoma of the nasopharynx Techniques and results . Cancer. 63:1989;2461-2467.
22. Wang C.C., Nakfoor B.M., Spiro I.J., Martins P. Role of accelerated fractionated irradiation for supraglottic carcinoma Assessment of results . Cancer J Sci Am. 3:1997;88-91.
23. Datta N.R., Choudhry A.D., Gupta S. Twice a day versus once a day radiation therapy in head and neck cancer. Int J Radiat Oncol Biol Phys. 17:1989;132.
24. Horiot J.C., Le-Fur R., NGuyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy . Radiother Oncol. 25:1992;231-241.
25. Sanchiz F., Milla A., Torner J., et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 19:1990;1347-1350.
26. Pinto L.H.J., Canary P.C.V., Araujo C.M.M., Bacelar S.C., Souhami L. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 21:1991;557-562.
27. Ang KK, Trotti A, Garden AS; et al. Importance of overall time factor in postoperative radiotherapy. In: Shah JP, Johnson JT, editors. 4th International Conference on Head and Neck Cancer. Toronto, Canada: The Society of Head and Neck Surgeons and American Society of Head and Neck Surgery; 1996. p. 231-235.
28. Awwad H.K., Khafagy Y., Barsoum M., et al. Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer Influence of tumour proliferation . Radiother Oncol. 25:1992;261-266.
29. Horiot J.C., Bontemps P., van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers Results of the EORTC 22851 randomized trial [see comments] . Radiother Oncol. 44:1997;111-121.
30. Johnson C.R., Schmidt-Ullrich R.K., Wazer D.E. Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer. 69:1992;2749-2754.
31. Overgaard J., Sand Hansen H., Overgaard M., et al. Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck A randomized multicenter study of 5 versus 6 fractions per week - report from the DAHANCA 7 trial . Int J Radiat Oncol Biol Phys. 39:1997;188.
32. Saunders M.I., Dische S., Barrett A., Parmar M.K., Harvey A., Gibson D. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer an interim report. CHART Steering Committee . Br J Cancer. 73:1996;1455-1462.
33. Maciejewski B., Skladowski K., Pilecki B., et al. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer Preliminary report on acute toxicity . Radiother Oncol. 40:1996;137-145.
34. Jackson S.M., Weir L.M., Hay J.H., Tsang V.H., Durham J.S. A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 43:1997;39-46.
35. Kaanders J.H., van-Daal W.A., Hoogenraad W.J., van-der-Kogel A.J. Accelerated fractionation radiotherapy for laryngeal cancer, acute, and late toxicity. Int J Radiat Oncol Biol Phys. 24:1992;497-503.
36. Brizel D.M. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 8:1998;237-246.
37. Trotti A. Toxicity antagonists in cancer therapy. Curr Opin Oncol. 9:1997;569-578.
38. Eisbruch A., Marsh L.H., Martel M.K., et al. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields Assessment of target coverage and noninvolved tissue sparing . Int J Radiat Oncol Biol Phys. 41:1998;559-568.
39. Eisbruch A., Ten Haken R.K., Kim H.M., Marsh L.H., Ship J.A. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 45:1999;577-587.
40. Wu Q., Manning M., Schmidt-Ullrich R., Mohan R. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers A treatment design study . Int J Radiat Oncol Biol Phys. 46:2000;195-205.
41. Fu K.K. Combined modality therapy for head and neck cancer. Oncology. 11:1997;1781-1796.
42. Wendt T.G., Grabenbauer G.G., Reodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer A randomized multicenter study . J Clin Oncol. 16:1998;1318-1324.
43. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma [see comments]. J Natl Cancer Inst. 91:1999;2081-2086.
44. Wheeler RH, Spencer S, Buchsbaum D, Robert F. Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer. Curr Opin Oncol 1999;11:187-190.